Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Razoxane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 3/20 | 1.00 |
| ▸ | TOP2B known ✓ | Q02880 | 3/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexrazoxane SCHEMBL18400 | 1.00 | TOP2A (1.00) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Dexrazoxane SCHEMBL1586271 | 1.00 | TOP2A (1.00) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Razoxane SCHEMBL27174203 | 0.98 | TOP2A (0.96) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Razoxane SCHEMBL27748349 | 0.98 | TOP2A (0.96) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Dexrazoxane SCHEMBL18188 | 0.98 | TOP2A (0.96) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Dexrazoxane SCHEMBL18189 | 0.96 | TOP2A (0.93) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Dexrazoxane SCHEMBL27918475 | 0.96 | TOP2A (0.93) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Dexrazoxane SCHEMBL28086609 | 0.94 | TOP2A (0.89) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Dexrazoxane SCHEMBL5488431 | 0.91 | TOP2A (0.83) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Dexrazoxane SCHEMBL5295434 | 0.91 | TOP2A (0.83) | TOP2ATOP2BPTGS1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 29832 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SYSTIMMUNE INC (US) | 2026-05-21 | — | — | US | claimed |
| EP-4743490-A1 | HUMANIZED ANTI-CD7 ANTIBODY | Christian-Albrechts-Universität zu Kiel (DE) | 2026-05-20 | — | — | EP | claimed |
| WO-2026099502-A1 | NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2026-05-15 | — | — | WO | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-20260085100-A1 | METHODS OF ANTIGEN PRODUCTION | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2026-03-26 | — | — | US | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| EP-4698185-A1 | METHODS AND SYSTEMS FOR IMPROVING ANTI-CANCER THERAPIES | Osasuna Therapeutics SA (CH) | 2026-02-25 | — | — | EP | claimed |
| EP-0393575-B1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | SEARLE & CO (US) | 1994-03-16 | — | — | EP | claimed |
| WO-1993023075-A1 | TREATMENT OF VASCULAR LEAKAGE SYNDROME AND COLLAGENASE INDUCED DISEASE BY ADMINISTRATION OF MATRIX METALLOPROTEINASE INHIBITORS | ONCOLOGIX, INC. (US) | 1993-11-25 | — | — | WO | claimed |
| WO-1993021938-A1 | METHODS FOR TREATING CANCER USING HIGH-DOSE EPIRUBICIN | ADRIA LABORATORIES (US) | 1993-11-11 | — | — | WO | claimed |
| US-5242901-A | Bisdioxopiperazine compounds for cardiovascular disorders | NEW YORK UNIVERSITY (US) | 1993-09-07 | — | — | US | claimed |
| WO-1992008460-A1 | BIS-DIOXOPIPERAZINES FOR TREATING LIVER TUMOURS | WINDLESHAW ENTERPRISES LIMITED (GB) | 1992-05-29 | — | — | WO | claimed |
| WO-1990012590-A1 | TREATMENT OF OCULAR DISEASE BY MODULATION OF MATRIX METALLOPROTEINASES AND THEIR INHIBITOR | STATE OF OREGON, STATE BOARD OF HIGHER EDUCATION, OREGON HEALTH SCIENCES UNIVERSITY (US) | 1990-11-01 | — | — | WO | claimed |
| EP-0393575-A1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | G.D. Searle & Co. (US) | 1990-10-24 | — | — | EP | claimed |
| US-4963679-A | Process for preparing bis (3,5-dioxopiperazinyl) alkanes or alkenes | ERBAMONT, INC. (US) | 1990-10-16 | — | — | US | claimed |
| EP-0330381-A1 | Process for preparing bis (3,5-dioxopiperazinyl) alkanes or alkenes | ERBAMONT, INC. (US) | 1989-08-30 | — | — | EP | claimed |
| US-4275063-A | 1,2-BIS(3,5-DIOXOPIPERAZIN-YL)PROPANE FOR TREATMENT OF CANCER IN HUMANS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1981-06-23 | — | — | US | claimed |